However, it is not clear the extent to which the treatment also decreased WAT inflammation, thereby contributing to the alleviation of the NASH phenotype; although MCP1 inhibition is expected to also decrease WAT inflammation. Here, CCL2 is linked to metabolic dysfunction-associated steatohepatitis.